MARCH2多克隆抗体的制备与鉴定及其在组织和细胞系中的表达与亚细胞结构中的定位

Preparation and Identification of MARCH2 Polyclonal Antibodies and Their Expression and Subcellular Structural Localization in Tissues and Cell Lines

摘要: 目的：探讨MARCH2多克隆抗体的制备、鉴定与纯化的方法以及其在组织和细胞系中的表达情况、在亚细胞结构中的定位情况。方法：利用DNAstar软件对MARCH2蛋白的抗原性等进行分析，化学合成MARCH2短肽，制备成完全抗原免疫家兔，获取血清，纯化，用Western blot、Elisa、免疫荧光进行鉴定。用RT-PCR检测MARCH2在细胞系中的表达情况，用Western blot检测MARCH2在组织中的表达情况。用免疫荧光法及激光共聚焦显微镜分析检测MARCH2在亚细胞结构中的定位。结果：成功制备完全抗原免疫家兔，纯化出多克隆抗体，用Western blot、Elisa、免疫荧光法证实多克隆抗体制备成功。利用半定量RT-PCR方法，在32种细胞系中检测了MARCH2 mRNA的表达水平，结果显示，MARCH2呈广泛表达，在HeLa、U2OS、HCT116、COS7细胞中表达最高，在SKBR3、HGC-27、MGC-803细胞中低表达。利用组织芯片及免疫组织化学方法进一步分析了其在正常组织及肿瘤组织中的表达情况，染色结果显示，MARCH2呈广泛表达，在前列腺、肝组织中呈高表达，在横纹肌、甲状腺组织中呈低表达，主要在胞浆中呈现弥漫均匀细颗粒状分布。此外，MARCH2表达因肿瘤类型的不同有差异。与对应的正常组织相比，MARCH2在某些肿瘤(如前列腺癌、肝癌)组织中表达降低，而在某些肿瘤(如食管癌、结肠癌)组织中表达增高。用免疫荧光法及激光共聚焦显微镜分析检测MARCH2在亚细胞结构中的定位，发现MARCH2与内质网、高尔基体共定位，与溶酶体、内体部分共定位，与线粒体没有共定位。结论：成功获得了MARCH2多克隆抗体，为进一步研究MARCH2蛋白的功能奠定了基础。MARCH2在不同类型肿瘤中的差异表达及其在亚细胞结构中的定位高度提示MARCH2在肿瘤发生发展中具有重要的潜在应用价值。

Abstract: Aims: To explore the preparation, identification, and purification methods of MARCH2 polyclonal antibodies, as well as their expression and subcellular structural localization in tissues and cell lines. Methods: DNAstar software was used to analyze the antigenicity of MARCH2 protein, and MARCH2 short peptides were chemically synthesized to prepare complete antigen-immunized rabbits. Serum was obtained, purified, and identified by Western blot, Elisa, and immunofluorescence. RT-PCR was used to detect the expression of MARCH2 in cell lines, and Western blot was used to detect the expression of MARCH2 in tissues. Immunofluorescence and confocal laser microscopy were used to analyze and detect the localization of MARCH2 in subcellular structures. Results: Fully antigen-immunized rabbits were successfully prepared, and polyclonal antibodies were purified. Western blot, Elisa, and immunofluorescence were used to confirm the successful preparation of polyclonal antibodies. Using semi-quantitative RT-PCR method, the expression level of MARCH2 mRNA was detected in 32 cell lines. The results showed that MARCH2 was widely expressed, with the highest expression in HeLa, U2OS, HCT116, and COS7 cells, and low expression in SKBR3, HGC-27, and MGC-803 cells. The expression of MARCH2 in normal and tumor tissues was further analyzed using tissue chips and immunohistochemical methods. The staining results showed that MARCH2 was widely expressed, with high expression in prostate and liver tissues, low expression in striated muscle and thyroid tissues, and mainly distributed in a diffuse and uniform granular form in the cytoplasm. In addition, MARCH2 expression varies depending on the type of tumor. Compared with corresponding normal tissues, MARCH2 expression is reduced in certain tumor tissues (such as prostate cancer and liver cancer), while it is increased in certain tumor tissues (such as esophageal cancer and colon cancer). Using immunofluorescence and laser confocal microscopy to analyze and detect the localization of MARCH2 in subcellular structures, it was found that MARCH2 was co-localized with the endoplasmic reticulum and Golgi apparatus, with lysosomes and endosomes partially, but not with mitochondria. Conclusions: MARCH2 polyclonal antibodies have been successfully obtained, laying the foundation for further research on the function of MARCH2 protein. The differential expression of MARCH2 in different types of tumors and its localization in subcellular structures highly suggest that MARCH2 has important potential application value in tumor occurrence and development.